Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence of Lamotrigine 100 mg in Healthy Male Volunteers
NCT06199791Phase 1Completed
- Sponsor
- Desitin Arzneimittel
- Start
- Apr 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of lamotrigine in epilepsy and bipolar disorder (BD) (2 arms), sponsored by Desitin Arzneimittel. Primary endpoints: Area under the curve at 72 hours and Maximal plasma concentration at 72 hours. Started Apr 2023; status: completed.
02
Drugs
lamotrigine
03
Conditions
epilepsybipolar disorder (BD)
Beyond the preview
Go deeper on NCT06199791.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199791.